Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoromethane SCHEMBL27755992 | 0.98 | TGFBR1 (0.64) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL2052409 | 0.87 | TGFBR1 (0.51) | TGFBR1MAPK14THRBALDH1A1 | |
| SCHEMBL373271 | 0.86 | TGFBR1 (0.59) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL2042895 | 0.85 | TGFBR1 (0.49) | TGFBR1MAPK14THRB | |
| SCHEMBL5496438 | 0.85 | TGFBR1 (0.56) | TGFBR1MAPK14THRB | |
| SCHEMBL2044086 | 0.85 | TGFBR1 (0.49) | TGFBR1MAPK14THRBTGFBR2CSNK1A1 | |
| SCHEMBL23409663 | 0.84 | TGFBR1 (0.54) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL6683670 | 0.84 | TGFBR1 (0.48) | TGFBR1MAPK14THRBTGFBR2CSNK1A1 | |
| SCHEMBL373665 | 0.83 | TGFBR1 (0.56) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL29547877 | 0.83 | TGFBR1 (0.56) | TGFBR1MAPK14THRBTGFBR2ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| EP-4065572-A1 | BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | Origo Biopharma, S.L. (ES) | 2022-10-05 | — | — | EP | claimed |
| US-20220106564-A1 | COMPOSITION AND KIT FOR DIFFERENTIATION OF STEM CELLS INTO NEURAL CREST STEM CELLS, INCLUDING INHIBITOR OF TGF-BETA I RECEPTOR AND BMP INHIBITOR, AND METHOD USING SAME | CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-04-07 | — | — | US | claimed |
| WO-2020145708-A1 | COMPOSITION AND KIT FOR DIFFERENTIATION OF STEM CELLS INTO NEURAL CREST STEM CELLS, INCLUDING INHIBITOR OF TGF-BETA I RECEPTOR AND BMP INHIBITOR, AND METHOD USING SAME | 차의과학대학교 산학협력단 | 2020-07-16 | — | — | WO | claimed |
| US-20200199538-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2020-06-25 | — | — | US | claimed |
| EP-3350313-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | Agency For Science, Technology And Research (A*star) (SG) | 2018-07-25 | — | — | EP | claimed |
| WO-2017048193-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2017-03-23 | — | — | WO | claimed |
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON RESEARCH, LTD. (US) | 2012-05-10 | — | — | US | claimed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | claimed |
| CN-101330914-A | Control of intraocular pressure using ALK5 modulation agents | ALCON INC (CH) | 2008-12-24 | — | — | CN | claimed |
| EP-1959949-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | Alcon, Inc. (CH) | 2008-08-27 | — | — | EP | claimed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | claimed |
| WO-2007070866-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | WO | claimed |
| WO-2004026302-A1 | METHODS OF INHIBITING TGF BETA WITH SUBSTITUTED PYRAZOLES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | claimed |
| CN-122036718-A | ALK5 inhibitor and preparation method and application thereof | 安炎达医药技术(广州)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-116323601-B | 2- (3-Pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl) -acetamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 阿戈麦布西班牙股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12577230-B2 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | AGOMAB SPAIN S.L.U. (ES) | 2026-03-17 | — | — | US | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| WO-2004026302-A1 | METHODS OF INHIBITING TGF BETA WITH SUBSTITUTED PYRAZOLES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577230-B2 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | TGFBR1, TGFBR2, ACVR1 | TGFBR1 1/4885MAPK14 845/4885THRB 206/4885 |
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885THRB 314/4885 |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885THRB 314/4885 |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885THRB 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.